Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.

Add Yahoo as a preferred source to see more of our stories on Google. Demis Hassabis speaks during the 56th annual World Economic Forum (WEF) meeting in Davos, Switzerland, January 20, 2026.

Alphabet's AI drug development subsidiary Isomorphic Labs is aiming to initiate clinical trials for its AI-developed oncology drugs. In an interview with Fortune, Isomorphic Labs president Colin ...

In 2024, Demis Hassabis won a Nobel Prize in chemistry for his work in predicting protein structures through his company, Isomorphic Labs. The lab, which broke off from Google's DeepMind in 2021, ...

Near.AI introduces a secure, private, Rust-based version of OpenClaw called IronClaw, Olas prediction agents unleashed ...